Daily Recap - WEDNESDAY
Join panelists Drs. Janet Pope, Richard Conway, Meral El Ramahi and Jack Cush recap the best presentations presented on day four of the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →What's hot
View all perspectives
What's Hot
EXXELERATE Study: Do High RF Titers Impact Response to TNF Inhibitors?
Dr. Jonathan Kay discusses abstract 2148 with Dr. Josef Smolen at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Bimekizumab in Active AS: 5 Year Study
Dr. Atul Deodhar reporting on abstract 0519 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cannabinoid Receptor in RA Patients
Dr. Arthur Kavanaugh discusses abstract 0025 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Treatments in SpA
Dr. Rachel Tate and Dr. Catherine Blakewell discuss treatment options patients in spondyloarthritis at the 2023 ACR Convergence meeting in San Diego, CA. Abstracts discussed include 0520, 0530, 0521 and 0529.
Watch video →
PR3+ in Lupus Nephritis
Dr. Jack Cush discusses abstract 2427 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Simulated Trials to Counter ORAL Survelliance
Dr. Jack Cush and Dr. Janet Pope at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Difficult to Treat axSpA
Dr. Peter Nash reports on abstracts 0514 and 0538 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Window of Opportunity in PsA
Dr. Peter Nash discusses a study that looks at the window of opportunity for treatment of PsA at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
TMP SMX Prophylaxis in GPA
Dr. Jack Cush and Dr. Janet Pope discuss abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The FOREMOST Study: Apremilast in PsA
Dr. Peter Nash reports on abstract 1691 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The SMART Study: Split Dose Oral Methotrexate
Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego.
Watch video →
Real World Experience with PEXIVAS Low Steroid Taper
Dr. Mike Putman discusses abstract 0725 with Dr. Sophie Nagle at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
Read more →
#ACRbest Abstracts – Day 2
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more.
Read more →
Effects of Apremilast on Cardiometabolic Effects in PsA
Dr. Peter Nash discusses abstract 1414 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
An Interview with Kevin Winthrop: Three Questions About COVID 19
Drs. Jack Cush and Kevin Winthrop discuss COVID 19 at 2023 ACR Convergence in San Diego, CA.
Watch video →
Biologics as First-line Therapy for PMR and GCA?
Dr. Eric Dein talks with Dr. Philip Seo, one of two panelists for the Great Debate: Should PMR and GCA Be Treated with Advanced Therapies at Disease Onset? at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Dr. John Cush RheumNow
2 years ago
JAKne? Systematic review &meta-analysis (25 studies, 10 839 pts), JAK inhibitor use was associated with an elevated odds of acne (OR 3-5 for UPA, TOFA, BARI, Deucra; but higher for abrocitinib (OR 13.5). Seen in Derm pts but hardly at all in Rheum pts https://t.co/0XYeLLPDlK https://t.co/xN0PR1gj08
Dr. John Cush RheumNow
2 years ago
Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure
Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/KtdQgTvw4o https://t.co/R70sj3oYPH
Dr. John Cush RheumNow
2 years ago
Genetic links for Raynauds Phen (RP): Large GWAS study of 5147 RP cases in the UK Biobank cohort shows 2 robust and strong (p < 4.8 × 10−13) novel loci A) ADRA2A (rs7090046, OR per allele: 1.26) & B) IRX1 (rs12653958, OR: 1.17) as candidate causal genes https://t.co/Jho4CKmITU https://t.co/Gstxdejpc0
Dr. John Cush RheumNow
2 years ago
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today!
https://t.co/7OsdPYWukv https://t.co/QoCxR04bJD
Dr. John Cush RheumNow
2 years ago
When #PMR Strikes Young, It Hits Hard
In this blogpost I want to talk about “young PMR”: when people develop PMR in what should be the prime of their lives. By this I mean people under 65, and even people under 50.
https://t.co/jHlppnddFf https://t.co/aB81hrYyHX
Dr. John Cush RheumNow
2 years ago
Controversies in #PMR
A TNR Panel discussion on controversies in PMR: diagnosis, imaging, PCP roles, Lumping vs. Splitting.
Featuring Drs. Sarah Mackie, Wolfgang Schmidt, and Len Calabrese.
Moderated by Dr. David Liew.
https://t.co/QLkypnPA2G https://t.co/y5EiLkB2yq
My colleague says, “I simply refer to physiotherapy. I don’t have time to discuss exercises, we need that time to discuss medications, side-effects, etc.” I sympathise. How do we promote activity and muscle strength among our patients?
Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.
Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.
#PMR Polymyalgia rheumatica is very common, yet there is little research on the Dx & Management of PMR by #PCPs! Mayo study prevalence 701 per 100,000 (women=870 and men =508 per 100,000 population). https://t.co/7JZFeRPRnn
Dr. John Cush RheumNow
2 years ago
#PMR Mythbusters: PMR is Only Proximal
https://t.co/tRed7Zsaxi https://t.co/PWP5boH6NA
Among patients with systemic lupus erythematosus (SLE), high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black and Asian individuals, researchers found.
Dr. John Cush RheumNow
2 years ago
ACR 2022 Guideline on Glucocorticoid-Induced Osteoporosis
The ACR has published its updated recommendations for prevention and treatment of GIOP for patients receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily.
https://t.co/oKVovOafl7 https://t.co/irxsAxMwKA
Dr. John Cush RheumNow
2 years ago
#PMR and Telemedicine: do we really need an office visit?
Can we use a synchronous audiovisual visit or a rheumatology eConsult to evaluate the patient's symptoms quickly? Does it allow us to make an accurate diagnosis?
https://t.co/JTAYstzDk8 https://t.co/NNvYfdkm2K
Poster Hall